← Back to patent-cliff list
Deudextromethorphan/Bupropion Hydrochloride
Tier C — Watch / tradeDeudextromethorphan/Bupropion Hydrochloride
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SIGMAR1, NMDAR, PGY1, DAT, Adrenoceptors
Indications (approved)：Depressive disorder, Depression, Alzheimer's disease, Major depressive disorder
Regional status
US
-
EU
-
China
Phase III
2025-08-29
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Deudextromethorphan/Bupropion Hydrochloride?
Approved indications include: Depressive disorder, Depression, Alzheimer's disease, Major depressive disorder.
When does the Deudextromethorphan/Bupropion Hydrochloride patent expire?
No public expiry year is available for Deudextromethorphan/Bupropion Hydrochloride yet; this page updates once verified.
How do I get a quote for Deudextromethorphan/Bupropion Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30